{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:14:02Z","timestamp":1697699642072},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T00:00:00Z","timestamp":1180569600000},"content-version":"vor","delay-in-days":2098,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p> <jats:italic>The preferred initial agents for the treatment of high blood pressure are low\u2010dose thiazide diuretics, \u03b2 blockers, calcium antagonists, and angiotensin\u2010converting enzyme (ACE) inhibitors. In high\u2010risk patients, including those with diabetes, renal insufficiency, left ventricular dysfunction, and atherosclerosis, ACE inhibitors may have specific benefit in reducing cardiovascular morbidity and mortality. Omapatrilat, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase. Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin. Effective blood pressure control, especially in the high\u2010risk patient, usually necessitates combination therapy. A recent study randomized 274 subjects with mild to severe hypertension (stages 1\u20133 diastolic blood pressure elevation) and confirmed the benefits of omapatrilat combined with hydrochlorothiazide in patients not controlled on hydrochlorothiazide alone. The frequencies of adverse events, serious adverse events, and discontinuation attributed to adverse events were similar for omapatrilat and placebo. Furthermore, there were no clinically significant changes in serum creatinine, potassium, or other laboratory parameters. Adding omapatrilat to the background of hydrochlorothiazide treatment produced statistically significant additional reductions in trough diastolic and systolic blood pressures at weeks 4 and 8.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1524-6175.2001.00488.x","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T08:29:16Z","timestamp":1180600156000},"page":"307-312","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Antihypertensive Combination Therapy: Benefits of Low\u2010Dose Thiazide Diuretics in Conjunction With Omapatrilat, a Vasopeptidase Inhibitor"],"prefix":"10.1111","volume":"3","author":[{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,31]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.3.305"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"Evaluation, and Treatment of High Blood Pressure","volume":"157","author":"Joint National Committee, National High Blood Pressure Education Program: The Sixth Report of the Joint National Committee on Prevention, Detection","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_8_4_2","first-page":"151","volume":"17","author":"World Health Organization\u2010International Society of Hypertension Guidelines Subcommittee. 1999 World Health Organization\u2010International Society of Hypertension Guidelines for the Management of Hypertension","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.17.2645"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-5-199709010-00001"},{"key":"e_1_2_8_11_2","first-page":"41","article-title":"Hypertension in type II diabetes: update on therapy","volume":"1","author":"Sowers JR","year":"1999","journal-title":"J Clin Hypertens"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.5.1021"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16225"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"issue":"1","key":"e_1_2_8_15_2","first-page":"S37","article-title":"Vasopeptidase inhibition: a new concept in blood pressure management","volume":"17","author":"Burnett JC","year":"1999","journal-title":"J Hypertens"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00205-8"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00607-5"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540400043029"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281303"},{"key":"e_1_2_8_20_2","first-page":"25","article-title":"Systemic review of antihypertensive therapies: does the evidence assist in choosing the first\u2010line drug","volume":"161","author":"Wright JM","year":"1999","journal-title":"CMAJ"},{"key":"e_1_2_8_21_2","first-page":"1090","article-title":"Does diuretic therapy increase the risk of renal cell carcinoma in women","volume":"83","author":"Grossman E","year":"1999","journal-title":"Am J Cardiol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.5.1025"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00510-6"},{"key":"e_1_2_8_24_2","first-page":"309A","article-title":"Omapatrilat, a novel vasopeptidase inhibitor reduces blood pressure in normotensive subjects [abstract]","volume":"33","author":"Wel\u2010Chi L","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"e_1_2_8_25_2","first-page":"8","article-title":"Black Americans have an increased rate of angiotensin\u2010converting enzyme inhibitor\u2010associated angioedema","volume":"60","author":"Brown NJ","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02602-7"},{"key":"e_1_2_8_27_2","first-page":"40","article-title":"Low\u2010dose combination therapy as first\u2010line hypertension treatment for blacks and nonblacks","volume":"91","author":"Prisant LM","year":"1999","journal-title":"J Natl Med Assoc"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392701"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-6175.2001.00488.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-6175.2001.00488.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:53:03Z","timestamp":1697633583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-6175.2001.00488.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1111\/j.1524-6175.2001.00488.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-6175.2001.00488.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}